167 In the index

CJC-1295 CJC

A modified version of a natural hormone-releasing signal, designed to last longer in the body and trigger growth hormone release. Small studies confirm it does raise growth hormone for an extended period, but there's little research on whether that actually improves body composition or performance.

Also known as CJC-1295 with DAC, CJC 1295, 62RC32V9N7, RefChem:918751, GRF 1-29 (CJC1295)

Effects Build muscle Heal

Routes Subcutaneous

Legal status Research chemical

WADA Banned at all times

Molecular Structure of C₁₆₅H₂₆₉N₄₇O₄₆

Drag to rotate · scroll to zoom

PubChem has no 3D conformer for this molecule, so this is the flat structure.

Chemistry

Formula: C165H269N47O46
Molar mass: 3647.2
CAS: 446262-90-4
PubChem CID: 91971820
IUPAC name: (3S)-4-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-6-[3-(2,5-dioxopyrrol-1-yl)propanoylamino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]-4-oxobutanoic acid
InChIKey: ZUQGTWKGESAQCD-ZGFIGYLBSA-N

Reported dosing

User-reported

What has been reported in the literature and by users. This is a record of what is done, not a recommendation.

Typical dose 100 mcg (no-DAC form) or 1-2 mg weekly (with DAC)

Reported range 100-300 mcg per dose, 1-3x/day (no-DAC); 1-2 mg once weekly (with DAC)

Route Subcutaneous injection

Frequency 1-3 times daily (no-DAC) or once weekly (with DAC)

Duration 8-12 week course (unregulated use)

Not FDA-approved; no completed human trials for the DAC-modified version specifically. Dosing is entirely vendor/forum-derived.

Where this comes from User-reported/research-chemical vendor literature; limited early pharmacology data

There is no approved human dosing for this compound. The figures above are what users and vendors report, not what has been established as safe or effective. Treat them as a record of what is done, not as guidance.

Variants

Name	Abbr	Route	Notes
CJC-1295 with DAC	CJC-DAC	Subcutaneous	Drug affinity complex version, roughly week-long action.
CJC-1295 without DAC	CJC-ND	Subcutaneous	Short-acting version, effectively Mod GRF 1-29.